Opioid control of luteinizing hormone secretion in patients with hirsutism and hyperandrogenemia.
The present study was designed to evaluate the influence of hyperandrogenemia on the activity of the opioid system regulating LH secretion in menstruating women. Ten subjects presenting with hirsutism and hyperandrogenemia and 9 healthy normally cyclic subjects participated in the study. Naloxone or saline was administered on 2 different days both during the follicular (6-8 days after menstrual bleeding) and during the luteal phase of the menstrual cycle. Naloxone significantly increased plasma LH levels in the luteal, but not during the follicular phase of the cycle in both subject groups. It may be inferred from these observations that opioid-mediated inhibition of LH secretion is not altered in menstruating hyperandrogenic patients, suggesting that the circulating androgens are not an important determinant of the functional neuroendocrine activity of the opioid system.
D000328:Adult; D000728:Androgens / Q000097:blood*; D004723:Endorphins / Q000502:physiology*; D005260:Female; D006628:Hirsutism / Q000378:metabolism*; D006801:Humans; D007986:Luteinizing Hormone / Q000378:metabolism*; D008597:Menstrual Cycle; D008598:Menstruation; D009270:Naloxone / Q000494:pharmacology; D011957:Receptors, Opioid / Q000187:drug effects
D000728:Androgens; D004723:Endorphins; D011957:Receptors, Opioid; D009270:Naloxone; D007986:Luteinizing Hormone